[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

11 clusters · 6 sources · 63 days · First seen · Last updated

CSL Ltd share price volatility and recovery efforts

Overview

CSL Ltd’s shares experienced significant volatility throughout mid-2026. After hitting a nine-year low in early June, the stock saw a sharp rebound of approximately 35%, rising from $91 to $122.89. This recovery was largely attributed to sector rotation and valuation re-assessments rather than company-specific news, as investors weighed the firm’s stable dividend yield—roughly 3.15%—against operational headwinds. Despite the rally, sentiment remains cautious. Analysts have largely shifted to a ‘hold’ stance, citing concerns over US immunoglobulin supply constraints, China albumin pricing pressure, and the US$5 billion non-cash impairment from the Vifor acquisition. Additionally, uncertainty persists regarding the Tavneos product, which faces potential regulatory hurdles in the EU.

On 29 July, the company announced a next-generation plasma manufacturing plan using its patented Horizon 2 technology to boost immunoglobulin yields, triggering a 6% share price jump. Following the release of FY26 results, which reported revenue of US$15.8 billion and an underlying NPATA of US$3.1 billion against a statutory loss of $2.6 billion, the stock continued its upward trajectory.

By early September, shares had surged approximately 90% from the low of $90 reached in June, despite a minor dip to $171.21. Investors have largely looked past the statutory loss, noting it was driven by US$7.1 billion in non-cash pre-tax impairments and US$799 million in restructuring costs. For FY27, CSL expects underlying NPAT growth of approximately 5%, exceeding consensus estimates of 2%. While the Vifor division faces a projected 25% revenue decline due to competition in the iron generics market, growth is expected from the Behring and Seqirus divisions.

Entities

CSL Ltd · ASX · CSL Vifor · Seqirus · CSL Behring

Timeline

  1. 3 days ago

    [BUSINESS] 2 sources
    CSL Ltd shares surge 90% from 11-year low

    CSL Ltd shares have surged 90% from their 11-year low following a fiscal 2026 reset that cleared non-cash impairments from the balance sheet, setting a positive outlook for fiscal 2027.

  2. 11 days ago

    [BUSINESS] 2 sources
    CSL Ltd shares rebound 86% following FY26 results

    CSL Ltd shares have rebounded 86% from their June lows, driven by strong FY26 revenue of US$15.8 billion and a broader recovery in the Australian healthcare sector.

  3. 12 days ago

    [BUSINESS] 2 sources
    CSL and Coles Group report positive market performance in Australia

    Australian companies CSL Ltd and Coles Group Ltd report positive market performance, with CSL rebounding 88% from its June lows and Coles seeing a 12.65% year-to-date share price increase.

  4. 17 days ago

    [BUSINESS] 2 sources
    CSL Ltd approaches CEO succession and financial reset

    CSL Ltd is undergoing a leadership search for a permanent CEO while managing a financial reset and guiding toward steady earnings growth through its plasma-derived therapy business.

  5. 28 days ago

    [BUSINESS] 2 sources
    CSL Ltd shares rally ahead of FY26 financial results

    CSL Ltd shares are rallying ahead of FY26 results, as investors monitor CSL Behring's margins and the planned demerger of its Seqirus vaccine business.

  6. about 1 month ago

    [BUSINESS] 2 sources
    CSL Ltd shares slide as analysts weigh biotech prospects against Telix and HUB24

    CSL shares down 28% this year; analysts compare its stable biotech earnings to Telix's high‑valuation radiopharma prospects and HUB24's award‑winning wealth‑tech platform.

  7. about 1 month ago

    [BUSINESS] 2 sources
    CSL shares rise 6% on announcement of next‑gen plasma manufacturing plan

    CSL shares rose 6% after the biotech announced Horizon 2 plasma manufacturing trials to start in mid‑2027, using material from its Broadmeadows site and tied to an Illinois plant expansion.

  8. about 2 months ago

    [BUSINESS] 2 sources
    CSL Ltd shares edge up as analysts weigh recovery prospects

    CSL Ltd shares rose 1% to AUD 123.32 as analysts note recent gains but warn of US$5 bn impairments, FY26 revenue guidance below forecasts, and modest upside targets.

  9. about 2 months ago

    [BUSINESS] 2 sources
    CSL Ltd shares rebound modestly as brokers shift to cautious hold stance

    CSL Ltd shares rose to $122.29, up 15% this month but still down 29% YTD. Brokers now mostly hold, with average target $140.15 (15% upside) and mixed outlooks ahead of FY26 results.

  10. 2 months ago

    [BUSINESS] 2 sources
    CSL Ltd shares surge 35% on ASX since early June

    CSL Ltd shares jumped 35% on the ASX from early June, reaching $122.89, driven by sector rotation and valuation shifts, with FY26 guidance unchanged and analysts awaiting August results.

  11. 2 months ago

    [BUSINESS] 3 sources
    CSL Ltd shares slide as investors weigh growth outlook

    CSL Ltd shares have dropped 27% this year amid performance concerns, but strong dividend yield and long‑term demand for its plasma and vaccine products keep investors interested.

Sources

blog.flexcareers.com.au · fool.com.au · lesgrandsmaitres.fr · raskmedia.com.au · stocknews.com · switzer.com.au

This summary has been updated 7 times: see revision history